Follow
Meghan McCabe Pryor
Meghan McCabe Pryor
Associate Director, J&J Innovative Medicine
Verified email at its.jnj.com - Homepage
Title
Cited by
Cited by
Year
Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level
RB Moss, MMC Pryor, R Baillie, K Kudrycki, C Friedrich, M Reed, ...
PLoS One 15 (6), e0234683, 2020
322020
Orchestration of ErbB3 signaling through heterointeractions and homointeractions
M McCabe Pryor, MP Steinkamp, AM Halasz, Y Chen, S Yang, MS Smith, ...
Molecular biology of the cell 26 (22), 4109-4123, 2015
312015
Dynamic transition states of ErbB1 phosphorylation predicted by spatial stochastic modeling
MMC Pryor, ST Low-Nam, ÁM Halász, DS Lidke, BS Wilson, JS Edwards
Biophysical journal 105 (6), 1533-1543, 2013
252013
Mathematical simulation of membrane protein clustering for efficient signal transduction
K Radhakrishnan, Á Halász, MM McCabe, JS Edwards, BS Wilson
Annals of biomedical engineering 40, 2307-2318, 2012
242012
Analytical Solution of Steady State Equations for Chemical Reaction Networks with Bilinear Rate Laws.
AM Halász, HJ Lai, M McCabe Pryor, K Radhakrishnan, JS Edwards
IEEE/ACM transactions on computational biology and bioinformatics/IEEE, ACM, 2013
142013
Quantitative Systems Pharmacology Model of the Amyloid Pathway in Alzheimer’s Disease: Insights into the Therapeutic Mechanisms of Clinical Candidates
V Ramakrishnan, C Friedrich, C Witt, R Sheehan, M Pryor, JK Atwal, ...
CPT: Pharmacometrics & Systems Pharmacology, 2022
52022
Spatiotemporal modeling of membrane receptors
ÁM Halász, MMC Pryor, BS Wilson, JS Edwards
Modeling Cellular Systems, 1-37, 2017
32017
Minimal physiologically-based pharmacokinetic (mPBPK) metamodeling of target engagement in skin informs anti-IL17A drug development in psoriasis
VS Ayyar, JB Lee, W Wang, M Pryor, Y Zhuang, T Wilde, A Vermeulen
Frontiers in Pharmacology, 1138, 2022
22022
Multiscale modeling of cancer. bioRxiv
KA Norton, MMMC Pryor, AS Popel
22015
2 Strategic Vision for Integrated Process Analytical Technology and Advanced Control in Biologics Manufacturing
MMS Amand, PG Millili, MM McCabe, BA Ogunnaike
PAT Applied in Biopharmaceutical Process Development and Manufacturing: An …, 2011
22011
Brief report: higher fentanyl exposures require higher doses of naloxone for successful reversals in a quantitative systems pharmacology model
RB Moss, MMC Pryor, R Baillie, K Kudrycki, C Friedrich, M Reed, ...
12021
USING MECHANISTIC QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELS TO CONNECT BIOMARKERS TO CLINICAL DISEASE ACTIVITY SCORES-EXAMPLES IN ATOPIC DERMATITIS (AD) AND PSORIASIS (PSO).
C Friedrich, R Baillie, M Weis, M Pryor, V Hurez, K Kudrycki, M Reed
CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S115-S115, 2020
2020
Quantitative Systems Pharmacology Model to Quantify Benefits of DAAO Inhibition in Schizophrenia
S Iadevaia, C Friedrich, M Pryor, C Witt, L Zhang, L Xu, H Faessel, ...
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S103-S104, 2018
2018
Development of a Quantitative Systems Pharmacology (QSP) Model, the Respiratory PhysioPD (TM) Platform, to Investigate Biological Mechanisms Underlying Bronchoconstriction
C Friedrich, B Weber, M Pryor, C Witt, J Borghardt, B Disse, C Dallinger, ...
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S16-S17, 2018
2018
Using Mechanistic Physiological Models to Investigate Responder/Non-Responder Attributes Retrospectively and Prospectively to De-Risk Drug Development
C Friedrich, M Reed, R Baillie, K Kudrycki, M Weis, M Pryor, D Chung
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S78-S78, 2017
2017
PhysioPD™ Research Enhances Dermatology Research and Drug Development Using Mechanistic Physiological Modeling
C Friedrich, K Kudrycki, M Weis, M Pryor, V Hurez, R Baillie, M Reed
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S78-S79, 2017
2017
PhysioPD TM Research Utilizes Mechanistic Physiological Models to Enhance Immunology Research and Drug Development
K Kudrycki, M Weis, M Pryor, R Baillie, V Hurez, D Chung, M Reed, ...
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S51-S51, 2017
2017
717 Mechanistic physiological modeling as a tool for enhancing dermatology research
C Friedrich, K Kudrycki, M Weis, M Reed, M Pryor, R Baillie
Journal of Investigative Dermatology 137 (5), S123, 2017
2017
A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD).
CM Friedrich, J Soper, CM Witt, MM Pryor, L Martens, D Lee, K Larson, ...
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 43, S15-S15, 2016
2016
Toward a Predictive Model of Spontaneous Clustering of VEGF Receptors
E Güven, C Short, MMC Pryor, BS Wilson, JS Edwards, ÁM Halász
The Ninth q-bio Conference, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–20